METHODS: We performed a systematic review on studies of VE and immunogenicity (rSBA/hSBA titers) of participants aged 12-23 months for primary and 6-18 years for booster immunisation (last search: 18 August 2023). Risk of bias and certainty of evidence were evaluated (PROSPERO: CRD42020178773).
RESULTS: We identified 10 studies. Two studies reported VE of primary immunisation with MenC vaccines ranging between 90% (74.9 - 96.1) and 84.1% (41.5 - 95.7) for periods of 2 and 7 years, respectively. Eight studies reported immunogenicity of primary immunisation with MenC and/or MenACWY vaccines, of which two reported -in addition- on booster immunisation. The percentage of participants with protective rSBA titers was high after primary immunisation but waned over the following 6 years. A single booster at the age of 7 years or older seems to prolong protection for several years.
CONCLUSIONS: A single dose of MenC or MenACWY vaccine at 12-23 months of age provides robust protection against MenC IMD. Data on booster immunisation are sparse, but indicate prolonged protection for three years at least.
方法:我们对年龄为12-23个月的初次和6-18岁的加强免疫参与者的VE和免疫原性(rSBA/hSBA滴度)的研究进行了系统评价(最后一次搜索:2023年8月18日)。评估偏倚风险和证据的确定性(PROSPERO:CRD42020178773)。
结果:我们确定了10项研究。两项研究报告说,在2年和7年期间,用MenC疫苗进行初次免疫的VE介于90%(74.9-96.1)和84.1%(41.5-95.7)之间。分别。8项研究报道了用MenC和/或MenACWY疫苗初次免疫的免疫原性,其中两个报告了-另外-加强免疫。初次免疫后,具有保护性rSBA滴度的参与者百分比很高,但在接下来的6年里有所减弱。7岁或以上的单个助推器似乎可以延长保护数年。
结论:12-23月龄的单剂量MenC或MenACWY疫苗可提供针对MenCIMD的强大保护。关于加强免疫的数据很少,但表明至少三年的长期保护。